Literature DB >> 22791498

Normalisation of plasma growth hormone levels improved cardiac dysfunction due to acromegalic cardiomyopathy with severe fibrosis.

Fumiko Yokota1, Hiroshi Arima, Miho Hirano, Tomohiro Uchikawa, Yasuya Inden, Tetsuya Nagatani, Yutaka Oiso.   

Abstract

A 51-year-old man was referred to the Department of Cardiology in our hospital due to severe congestive heart failure and ventricular arrhythmias in March 2008. He had repeated ventricular tachycardia for years and the left ventricular ejection fraction (EF) was 11% on admission. A myocardial biopsy revealed that over 50% cardiomyocytes were replaced by fibrosis. Due to the typical acromegalic features, he was referred to the endocrinology department and diagnosed as acromegaly. He was treated with octreotide for 8 months followed by trans-sphenoidal surgery. The plasma levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) decreased by octreotide and normalised by surgery after which the cardiac function improved drastically. The current case demonstrates that cardiac dysfunction in acromegaly could be recovered by normalisation of GH and IGF-1 even in the presence of severe fibrosis in the myocardium.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22791498      PMCID: PMC3038016          DOI: 10.1136/bcr.12.2009.2559

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.

Authors:  A Colao; R Baldelli; P Marzullo; E Ferretti; D Ferone; P Gargiulo; M Petretta; G Tamburrano; G Lombardi; A Liuzzi
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  Histopathological improvement of acromegalic cardiomyopathy by intermittent subcutaneous infusion of octreotide.

Authors:  M Nishiki; Y Murakami; M Sohmiya; K Koshimura; K Inoue; Y Goto; N Nakamura; Y Kato
Journal:  Endocr J       Date:  1997-10       Impact factor: 2.349

3.  Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension?

Authors:  R López-Velasco; H F Escobar-Morreale; B Vega; E Villa; J M Sancho; J L Moya-Mur; R García-Robles
Journal:  J Clin Endocrinol Metab       Date:  1997-04       Impact factor: 5.958

4.  Acromegalic heart disease: influence of treatment of the acromegaly on the heart.

Authors:  R P Hayward; R W Emanuel; J D Nabarro
Journal:  Q J Med       Date:  1987-01

5.  Dramatic improvement of severe dilated cardiomyopathy in an acromegalic patient after treatment with octreotide and trans-sphenoidal surgery.

Authors:  V Legrand; A Beckers; V T Pham; J C Demoulin; A Stevenaert
Journal:  Eur Heart J       Date:  1994-09       Impact factor: 29.983

6.  Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.

Authors:  A Colao; A Cuocolo; P Marzullo; E Nicolai; D Ferone; A M Della Morte; R Pivonello; M Salvatore; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

7.  Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes.

Authors:  H Ito; M Hiroe; Y Hirata; M Tsujino; S Adachi; M Shichiri; A Koike; A Nogami; F Marumo
Journal:  Circulation       Date:  1993-05       Impact factor: 29.690

8.  Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

Authors:  S M Orme; R J McNally; R A Cartwright; P E Belchetz
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

Review 9.  Growth hormone and the heart.

Authors:  L Saccà; A Cittadini; S Fazio
Journal:  Endocr Rev       Date:  1994-10       Impact factor: 19.871

10.  Myocardial involvement in acromegaly.

Authors:  P A van den Heuvel; H R Elbers; H W Plokker; A V Bruschke
Journal:  Int J Cardiol       Date:  1984-10       Impact factor: 4.164

View more
  4 in total

1.  Face the truth: a 76-year-old man with chronic heart failure of unknown origin.

Authors:  Tomoharu Suzuki; Yasuharu Tokuda
Journal:  BMJ Case Rep       Date:  2014-05-21

2.  Increased fibrosis: A novel means by which GH influences white adipose tissue function.

Authors:  Lara A Householder; Ross Comisford; Silvana Duran-Ortiz; Kevin Lee; Katie Troike; Cody Wilson; Adam Jara; Mitchell Harberson; Edward O List; John J Kopchick; Darlene E Berryman
Journal:  Growth Horm IGF Res       Date:  2017-12-20       Impact factor: 2.372

3.  Transcriptome profiling of insulin sensitive tissues from GH deficient mice following GH treatment.

Authors:  Darlene E Berryman; Edward O List; Jonathan A Young; Mat Buchman; Silvana Duran-Ortiz; Colin Kruse; Stephen Bell; John J Kopchick
Journal:  Pituitary       Date:  2021-01-12       Impact factor: 3.599

4.  Normalization of plasma growth hormone alleviated malignant ventricular tachycardia in acromegaly.

Authors:  Zhi-Hao Liu; Kang Li; Yan-Sheng Ding; Jian-Xing Qiu; Steven Siyao Meng; Mohetaboer Momin; Sheng-Cong Liu; Tie-Ci Yi; Jian-Ping Li
Journal:  J Geriatr Cardiol       Date:  2018-08       Impact factor: 3.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.